Here are the DEF 14A proxy statements from Inhibrx Biosciences, Inc. (INBX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow INBX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INBX filings page.
Inhibrx Biosciences, Inc. is asking stockholders to vote at its virtual-only 2026 Annual Meeting on June 3, 2026. Stockholders will elect two Class II directors, Douglas G. Forsyth and Kimberly Manhard, to serve until 2029 and ratify BDO USA, P.C. as independent auditor for 2026.
The record date is April 7, 2026, when 14,607,286 common shares were outstanding and entitled to one vote each. The proxy also details board structure, committee memberships, director pay, and executive compensation, including 2025 total pay of $2,892,473 for CEO Mark P. Lappe, $923,696 for CFO Kelly D. Deck, and $1,435,940 for President David J. Matly.